Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 29, 2020

Pfizer gets FDA nod for Xeljanz to treat juvenile idiopathic arthritis

Pfizer has secured approval from the US Food and Drug Administration (FDA) for its Xeljanz (tofacitinib) to treat children and adolescents two years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).

Pfizer world headquarters in Manhattan, New York. (Credit: Coolcaesar)